title: A trial of human alpha interferon as an adjuvant agent in breast cancer after loco-regional recurrence.
abstract: Thirty-two women who had developed loco-regional recurrence of breast carcinoma were entered into a controlled trial of adjuvant alpha-interferon. All patients had histological confirmation of recurrence, local treatment with radiotherapy and negative staging investigations. They were then randomized to either observation alone, or treatment with human alpha interferon 3 x 10(6) units subcutaneously daily for 1 year. There were no differences detected in the rate of local or distant relapse. With this lack of clinically significant efficacy and a high incidence of side effects, it is concluded that alpha interferon is of doubtful value in the adjuvant treatment of breast cancer.
authors: ICRF Clinical Oncology Unit, Guy's Hospital, London, UK.
authors: I S
authors: IS
authors: Fentiman
authors: F R
authors: FR
authors: Balkwill
authors: J
authors: J
authors: Cuzick
authors: J L
authors: JL
authors: Hayward
authors: R D
authors: RD
authors: Rubens
mesh_terms: D000276:Adjuvants, Immunologic / Q000097:blood / Q000627:therapeutic use*; D000368:Aged; D001943:Breast Neoplasms / Q000401:mortality / Q000628:therapy*; D002277:Carcinoma / Q000401:mortality / Q000628:therapy*; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000097:blood / Q000627:therapeutic use*; D008408:Mastectomy; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000628:therapy*; D011897:Random Allocation
chemical_list: D000276:Adjuvants, Immunologic; D007370:Interferon Type I